<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524537</url>
  </required_header>
  <id_info>
    <org_study_id>P06-134</org_study_id>
    <nct_id>NCT00524537</nct_id>
  </id_info>
  <brief_title>A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)</brief_title>
  <official_title>A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Registry study is to evaluate the long-term safety and effectiveness of
      adalimumab in CD subjects who are treated as recommended in the product label.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Registry Treatment-Emergent Adverse Events (AEs)</measure>
    <time_frame>Registry treatment-emergent SAEs and AEs of special interest are summarized from the day of the first dose of Humira in the registry until 70 days after the last non-missing Humira injection date in the registry (up to approximately 6 years).</time_frame>
    <description>An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Registry treatment-emergent AEs are defined as any event that began or worsened in severity after the first dose of Humira in the registry. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.
For more details on adverse events please see the AE section below.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Total Score: Change From Baseline to Each Visit</measure>
    <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
    <description>The SIBDQ is a disease-specific health-related quality of life (HRQoL) questionnaire, able to detect and define meaningful clinical changes in inflammatory bowel disease (IBD) patients by measuring physical, social and emotional status. The SIBDQ consists of 10 questions, each question is scored on a scale from 1 (poor QoL) to 7 (good QoL). The scores are summed up and range from 10 (poor QoL) to 70 (good QoL). A higher score indicates a better HRQoL; a positive change from baseline indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment of Disease Activity (PGA): Change From Baseline to Each Visit</measure>
    <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
    <description>The PGA measures the physician's assessment of the patient's current disease activity from using 6 assessments (general well-being, abdominal pain, diarrhea, blood in stool, abdominal mass, and Crohn's disease-related complications). The PGA score is the sum of the subscores and ranges from 0 (very good) to approximately 25 (very bad). A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment: Special Health Problem (WPAI:SHP): Change in Mean Percentage of Work Time Missed (Absenteeism) From Baseline to Each Visit</measure>
    <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
    <description>Absenteeism, presented as the mean percentage of work time missed due to Crohn's Disease (as reported on the WPAI:SHP), and is calculated as: 100*number of hours of work missed due to psoriasis / (number of hours of work missed due to psoriasis + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WPAI:SHP: Change in Mean Percentage of Impairment While Working (Presenteeism) Due to Crohn's Disease From Baseline to Each Visit</measure>
    <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
    <description>Presenteeism (the extent to which CD decreased productivity) is presented as the mean percentage of impairment while working due to CD, and is calculated as: 100*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI:SHP is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WPAI:SHP: Change in Mean Percentage of Overall Work Impairment Due to Crohn's Disease From Baseline to Each Visit</measure>
    <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
    <description>The mean percentage of overall work impairment due to CD (based on the WPAI questionnaire) is presented, and is calculated as: Absenteeism (%) + extent to which CD decreased productivity (%)* [number of hours worked / (number of hours of work missed due to CD + number of hours worked)]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WPAI:SHP: Change in Mean Percentage of Activity Impairment Due to Crohn's Disease From Baseline to Each Visit</measure>
    <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
    <description>Activity impairment due to CD (the extent to which CD affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, and is calculated as 100*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU): Mean Number Of Visits At Physician's Office Due to CD at Each Study Visit</measure>
    <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
    <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations for their CD in the past 3 months. The mean number of visits at physician's office in the past 3 months is presented at each timepoint. N=number of participants with at least one visit at given timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU): Mean Number Of Visits At Emergency Room Due to CD at Each Study Visit</measure>
    <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
    <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to CD in the past 3 months. The mean number of visits at emergency room in the past 3 months is presented at each timepoint. N=number of participants with at least one visit at given timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU): Mean Number Of Admissions to Hospital Due to CD at Each Study Visit</measure>
    <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
    <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to CD in the past 3 months. The mean number of admissions to hospital in the past 3 months is presented at each timepoint. N=number of participants with data for &quot;total days in hospital&quot; and at least one admission to hospital at given timepoint..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization (HCRU): Mean Total Days In Hospital Due to CD at Each Study Visit</measure>
    <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
    <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to CD in the past 3 months. The mean total days in hospital in the past 3 months is presented at each timepoint. N=number of participants with data for &quot;total days in hospital&quot; at given timepoint.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5025</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Adalimumab (Humira) Treatment</arm_group_label>
    <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Crohn's disease who have been prescribed adalimumab according to the local
        label.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are newly prescribed HUMIRA® (adalimumab) therapy (have never been
             treated with adalimumab) or who are participants in Abbvie sponsored investigational
             Crohn's disease (CD) trials, are currently receiving adalimumab and for whom the
             treating physician has made the decision to continue with adalimumab therapy beyond
             the duration of the investigational trial.

          -  Subjects who were participants in AbbVie sponsored investigational Crohn's CD trials,
             who have not had dose interruptions since the last dose of study drug, where the
             Investigator can provide source documentation of dosing information.

          -  Subjects who are currently receiving adalimumab, as per the local approved label, who
             have not had dose interruptions since the induction dose of adalimumab where the
             Investigator can provide source documentation of dosing information.

          -  Subjects willing to consent to data being collected and provided to AbbVie.

          -  Subjects capable of and willing to give written informed consent and to comply with
             the requirements of the Registry study protocol.

        Exclusion Criteria:

        - Subjects should not be enrolled if they cannot be treated in accordance with the local
        product label.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Iceland</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <results_first_submitted>November 18, 2016</results_first_submitted>
  <results_first_submitted_qc>January 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2017</results_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 6 participants less than 18 years of age were enrolled in the study. Participants were permitted to re-enroll after discontinuing the study. Of the 2811 participants who discontinued study, 339 re-enrolled in the study; 102 participants discontinued from the study after re-enrollment.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adalimumab (Humira) Treatment</title>
          <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5025">All Treated Population: All participants who received at least 1 injection of Humira in the registry</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="2811">Discontinued from study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Re-enrolled</title>
              <participants_list>
                <participants group_id="P1" count="339">Discontinued from study and later re-enrolled in study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued After Re-enrollment</title>
              <participants_list>
                <participants group_id="P1" count="102">Discontinued from study after re-enrollment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2451">Still enrolled in study at the end of study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2574"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Treated Population: All participants who received at least 1 injection of Humira in the registry</population>
      <group_list>
        <group group_id="B1">
          <title>Adalimumab (Humira) Treatment</title>
          <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5025"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.8" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2869"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Registry Treatment-Emergent Adverse Events (AEs)</title>
        <description>An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Registry treatment-emergent AEs are defined as any event that began or worsened in severity after the first dose of Humira in the registry. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.
For more details on adverse events please see the AE section below.</description>
        <time_frame>Registry treatment-emergent SAEs and AEs of special interest are summarized from the day of the first dose of Humira in the registry until 70 days after the last non-missing Humira injection date in the registry (up to approximately 6 years).</time_frame>
        <population>All Treated Population: All participants who received at least 1 injection of Humira in the registry</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Registry Treatment-Emergent Adverse Events (AEs)</title>
          <description>An AE is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Registry treatment-emergent AEs are defined as any event that began or worsened in severity after the first dose of Humira in the registry. The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.
For more details on adverse events please see the AE section below.</description>
          <population>All Treated Population: All participants who received at least 1 injection of Humira in the registry</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5025"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Leading to Discontinuation of Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE Leading to Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Total Score: Change From Baseline to Each Visit</title>
        <description>The SIBDQ is a disease-specific health-related quality of life (HRQoL) questionnaire, able to detect and define meaningful clinical changes in inflammatory bowel disease (IBD) patients by measuring physical, social and emotional status. The SIBDQ consists of 10 questions, each question is scored on a scale from 1 (poor QoL) to 7 (good QoL). The scores are summed up and range from 10 (poor QoL) to 70 (good QoL). A higher score indicates a better HRQoL; a positive change from baseline indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
        <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
        <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with SIBDQ measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Total Score: Change From Baseline to Each Visit</title>
          <description>The SIBDQ is a disease-specific health-related quality of life (HRQoL) questionnaire, able to detect and define meaningful clinical changes in inflammatory bowel disease (IBD) patients by measuring physical, social and emotional status. The SIBDQ consists of 10 questions, each question is scored on a scale from 1 (poor QoL) to 7 (good QoL). The scores are summed up and range from 10 (poor QoL) to 70 (good QoL). A higher score indicates a better HRQoL; a positive change from baseline indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
          <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with SIBDQ measurements.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Month 12 (N=1712)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" spread="12.335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 24 (N=1319)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" spread="13.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 36 (N=1712)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="12.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 48 (N=969)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.51" spread="13.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 60 (N=837)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45" spread="13.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 72 (N=748)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" spread="12.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician's Global Assessment of Disease Activity (PGA): Change From Baseline to Each Visit</title>
        <description>The PGA measures the physician's assessment of the patient's current disease activity from using 6 assessments (general well-being, abdominal pain, diarrhea, blood in stool, abdominal mass, and Crohn's disease-related complications). The PGA score is the sum of the subscores and ranges from 0 (very good) to approximately 25 (very bad). A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
        <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
        <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with PGA measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician's Global Assessment of Disease Activity (PGA): Change From Baseline to Each Visit</title>
          <description>The PGA measures the physician's assessment of the patient's current disease activity from using 6 assessments (general well-being, abdominal pain, diarrhea, blood in stool, abdominal mass, and Crohn's disease-related complications). The PGA score is the sum of the subscores and ranges from 0 (very good) to approximately 25 (very bad). A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
          <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with PGA measurements.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3897"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Month 12 (N=3335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="4.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 24 (N=2856)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="5.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 36 (N=2629)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="5.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 48 (N=2403)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="5.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 60 (N=2162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="5.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 72 (N=1983)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="5.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Activity Impairment: Special Health Problem (WPAI:SHP): Change in Mean Percentage of Work Time Missed (Absenteeism) From Baseline to Each Visit</title>
        <description>Absenteeism, presented as the mean percentage of work time missed due to Crohn's Disease (as reported on the WPAI:SHP), and is calculated as: 100*number of hours of work missed due to psoriasis / (number of hours of work missed due to psoriasis + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
        <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
        <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with WPAI:SHP measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Productivity and Activity Impairment: Special Health Problem (WPAI:SHP): Change in Mean Percentage of Work Time Missed (Absenteeism) From Baseline to Each Visit</title>
          <description>Absenteeism, presented as the mean percentage of work time missed due to Crohn's Disease (as reported on the WPAI:SHP), and is calculated as: 100*number of hours of work missed due to psoriasis / (number of hours of work missed due to psoriasis + number of hours worked). WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
          <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with WPAI:SHP measurements.</population>
          <units>percentage of work time missed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1065"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Month 12 (N=829)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.92" spread="26.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 24 (N=612)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.02" spread="26.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 36 (N=507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.62" spread="29.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 48 (N=436)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.93" spread="31.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 60 (N=368)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.22" spread="29.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 72 (N=303)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.89" spread="26.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WPAI:SHP: Change in Mean Percentage of Impairment While Working (Presenteeism) Due to Crohn’s Disease From Baseline to Each Visit</title>
        <description>Presenteeism (the extent to which CD decreased productivity) is presented as the mean percentage of impairment while working due to CD, and is calculated as: 100*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI:SHP is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
        <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
        <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with WPAI:SHP measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>WPAI:SHP: Change in Mean Percentage of Impairment While Working (Presenteeism) Due to Crohn’s Disease From Baseline to Each Visit</title>
          <description>Presenteeism (the extent to which CD decreased productivity) is presented as the mean percentage of impairment while working due to CD, and is calculated as: 100*scale value of question 5 on the WPAI (between 0 and 10) / 10. WPAI:SHP is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
          <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with WPAI:SHP measurements.</population>
          <units>percentage of impairment while working</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Month 12 (N=914)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.00" spread="29.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 24 (N=697)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.04" spread="31.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 36 (N=577)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.84" spread="30.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 48 (N=493)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.09" spread="33.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 60 (N=418)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.21" spread="30.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 72 (N=361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.03" spread="29.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WPAI:SHP: Change in Mean Percentage of Overall Work Impairment Due to Crohn’s Disease From Baseline to Each Visit</title>
        <description>The mean percentage of overall work impairment due to CD (based on the WPAI questionnaire) is presented, and is calculated as: Absenteeism (%) + extent to which CD decreased productivity (%)* [number of hours worked / (number of hours of work missed due to CD + number of hours worked)]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
        <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
        <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with WPAI:SHP measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>WPAI:SHP: Change in Mean Percentage of Overall Work Impairment Due to Crohn’s Disease From Baseline to Each Visit</title>
          <description>The mean percentage of overall work impairment due to CD (based on the WPAI questionnaire) is presented, and is calculated as: Absenteeism (%) + extent to which CD decreased productivity (%)* [number of hours worked / (number of hours of work missed due to CD + number of hours worked)]. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
          <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with WPAI:SHP measurements.</population>
          <units>percentage of overall work impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1061"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Month 12 (N=821)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.48" spread="32.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 24 (N=605)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.95" spread="35.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 36 (N=498)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.78" spread="34.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 48 (N=435)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.15" spread="36.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 60 (N=365)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.14" spread="34.696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 72 (N=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.33" spread="34.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WPAI:SHP: Change in Mean Percentage of Activity Impairment Due to Crohn’s Disease From Baseline to Each Visit</title>
        <description>Activity impairment due to CD (the extent to which CD affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, and is calculated as 100*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
        <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
        <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with WPAI:SHP measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>WPAI:SHP: Change in Mean Percentage of Activity Impairment Due to Crohn’s Disease From Baseline to Each Visit</title>
          <description>Activity impairment due to CD (the extent to which CD affected the ability to perform usual daily activities) is presented as the mean percentage of activity impairment, and is calculated as 100*scale value of WPAI question 6 (between 0 and 10) / 10. WPAI is a questionnaire used to evaluate lost productivity; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. A negative change in score indicates improvement. N=the number of participants with available data at both baseline and given timepoint.</description>
          <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with WPAI:SHP measurements.</population>
          <units>percentage of activity impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Month 12 (N=1665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.93" spread="30.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 24 (N=1286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.75" spread="33.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 36 (N=1095)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.07" spread="32.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 48 (N=944)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.14" spread="33.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 60 (N=817)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.78" spread="31.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Month 72 (N=718)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.13" spread="29.533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU): Mean Number Of Visits At Physician's Office Due to CD at Each Study Visit</title>
        <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations for their CD in the past 3 months. The mean number of visits at physician's office in the past 3 months is presented at each timepoint. N=number of participants with at least one visit at given timepoint.</description>
        <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
        <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with at least 1 visit at physician's office.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU): Mean Number Of Visits At Physician's Office Due to CD at Each Study Visit</title>
          <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations for their CD in the past 3 months. The mean number of visits at physician's office in the past 3 months is presented at each timepoint. N=number of participants with at least one visit at given timepoint.</description>
          <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with at least 1 visit at physician's office.</population>
          <units>number of visits at physician's office</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5025"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="2.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=780)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="2.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (N=1042)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="2.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (N=1003)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="3.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (N=869)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.38" spread="2.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (N=798)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="2.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 72 (N=711)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="2.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU): Mean Number Of Visits At Emergency Room Due to CD at Each Study Visit</title>
        <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to CD in the past 3 months. The mean number of visits at emergency room in the past 3 months is presented at each timepoint. N=number of participants with at least one visit at given timepoint.</description>
        <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
        <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with at least 1 visit at emergency room.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU): Mean Number Of Visits At Emergency Room Due to CD at Each Study Visit</title>
          <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to CD in the past 3 months. The mean number of visits at emergency room in the past 3 months is presented at each timepoint. N=number of participants with at least one visit at given timepoint.</description>
          <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with at least 1 visit at emergency room.</population>
          <units>number of visits at emergency room</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (N=162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (N=134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (N=131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (N=124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 72 (N=97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU): Mean Number Of Admissions to Hospital Due to CD at Each Study Visit</title>
        <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to CD in the past 3 months. The mean number of admissions to hospital in the past 3 months is presented at each timepoint. N=number of participants with data for &quot;total days in hospital&quot; and at least one admission to hospital at given timepoint..</description>
        <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
        <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with data for &quot;total days in hospital&quot; and at least one admission to hospital.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU): Mean Number Of Admissions to Hospital Due to CD at Each Study Visit</title>
          <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to CD in the past 3 months. The mean number of admissions to hospital in the past 3 months is presented at each timepoint. N=number of participants with data for &quot;total days in hospital&quot; and at least one admission to hospital at given timepoint..</description>
          <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with data for &quot;total days in hospital&quot; and at least one admission to hospital.</population>
          <units>number of admissions to hospital</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5025"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (N=255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="0.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (N=229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (N=180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="2.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (N=197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="1.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 72 (N=180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="3.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization (HCRU): Mean Total Days In Hospital Due to CD at Each Study Visit</title>
        <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to CD in the past 3 months. The mean total days in hospital in the past 3 months is presented at each timepoint. N=number of participants with data for &quot;total days in hospital&quot; at given timepoint.</description>
        <time_frame>Baseline (Enrollment) and 12, 24, 36, 48, 60, and 72 Months</time_frame>
        <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with data for &quot;total days in hospital&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (Humira) Treatment</title>
            <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization (HCRU): Mean Total Days In Hospital Due to CD at Each Study Visit</title>
          <description>The HCRU assesses the frequency of unscheduled outpatient visits, emergency room visits, or hospitalizations due to CD in the past 3 months. The mean total days in hospital in the past 3 months is presented at each timepoint. N=number of participants with data for &quot;total days in hospital&quot; at given timepoint.</description>
          <population>All participants in the All Treated Population (received at least 1 injection of Humira in the registry) with data for &quot;total days in hospital&quot;.</population>
          <units>total days in hospital</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.80" spread="3.259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (N=230)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.19" spread="9.801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (N=255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.17" spread="11.753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (N=229)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.75" spread="19.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48 (N=180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.37" spread="10.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60 (N=195)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.03" spread="12.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 72 (N=180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.27" spread="13.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Registry treatment-emergent SAEs and AEs of special interest are summarized from the day of the first dose of Humira in the registry until 70 days after the last non-missing Humira injection date in the registry (up to approximately 6 years).</time_frame>
      <desc>Treatment-emergent AEs (TEAEs) of special interest were intended to be collected; however, if TEAEs were spontaneously reported by the participant, they were also analyzed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adalimumab (Humira) Treatment</title>
          <description>Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1853" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>AUTOIMMUNE HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BONE MARROW OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EOSINOPHILIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FEBRILE BONE MARROW APLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IMMUNE THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LYMPHADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SICKLE CELL ANAEMIA WITH CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BRADYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>VITELLO-INTESTINAL DUCT REMNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>BASEDOW'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLEPHARITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CORNEAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EPISCLERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RETINOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SCLERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ULCERATIVE KERATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VISUAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ADHESIONS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABNORMAL FAECES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL SPHINCTER ATONY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANOGENITAL DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANORECTAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANORECTAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>APHTHOUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>AUTOIMMUNE PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COELIAC ARTERY COMPRESSION SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLON DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLONIC FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="606" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEFAECATION URGENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIARRHOEA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIEULAFOY'S VASCULAR MALFORMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DUODENAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTEROCOLONIC FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTEROCUTANEOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FAECAL INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FAECALOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FAECES DISCOLOURED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FEMORAL HERNIA STRANGULATED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FISTULA OF SMALL INTESTINE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FOOD POISONING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FREQUENT BOWEL MOVEMENTS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FUNCTIONAL GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTRIC FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERNIAL EVENTRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ILEAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ILEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INCARCERATED UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFLAMMATORY BOWEL DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFREQUENT BOWEL MOVEMENTS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERNAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL DILATATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL MUCOSAL HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTUSSUSCEPTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>JEJUNAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>JEJUNAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOCALISED INTRAABDOMINAL FLUID COLLECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MEGACOLON</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MESENTERIC VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NARCOTIC BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OMENTAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PANCREATIC PSEUDOCYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PANCREATITIS NECROTISING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PANCREATITIS RELAPSING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PAPILLA OF VATER STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PHARYNGO-OESOPHAGEAL DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMATOSIS INTESTINALIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POUCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROCTITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PSEUDOPOLYPOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL SPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SHORT-BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VOLVULUS OF SMALL BOWEL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CATHETER SITE DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEVICE ISSUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEVICE LEAKAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRUG EFFECT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRUG WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FACE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERTHERMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IMPAIRED HEALING</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOCAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOCALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NO THERAPEUTIC RESPONSE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SENSATION OF FOREIGN BODY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TREATMENT FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AUTOIMMUNE HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS SCLEROSING</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CIRRHOSIS ALCOHOLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GALLBLADDER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATIC NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATITIS ALCOHOLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATOCELLULAR INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATORENAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NODULAR REGENERATIVE HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PORTAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PORTAL VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>AMYLOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CONTRAST MEDIA ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>KIDNEY TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABSCESS INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABSCESS JAW</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>APPENDICITIS PERFORATED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARTHRITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BARTHOLIN'S ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BARTHOLINITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BILIARY SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BRAIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BRONCHITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BRONCHOPULMONARY ASPERGILLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CAMPYLOBACTER GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CAMPYLOBACTER INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CANDIDA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CANDIDA PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS INFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIARRHOEA INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DISSEMINATED TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EPSTEIN-BARR VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FALLOPIAN TUBE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FUNGAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FUNGAL PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GAS GANGRENE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NOROVIRUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GENITAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GENITAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GENITAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>H1N1 INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMATOMA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMOPHILUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HELICOBACTER GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HELICOBACTER INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATITIS C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERPES OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERPES OPHTHALMIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERPES VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER OTICUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HIV INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IMPETIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INCISION SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFECTED CYST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFECTION PARASITIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFECTIVE EXACERBATION OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>KIDNEY INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LEGIONELLA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LISTERIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LYMPHADENITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MASTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MASTOIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MENINGITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MUSCLE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OPHTHALMIC HERPES SIMPLEX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OVERGROWTH BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PAROTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PELVIC ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PELVIC INFLAMMATORY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERINEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERIORBITAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERITONEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERITONITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERIUMBILICAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERTUSSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECII PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA CHLAMYDIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA MYCOPLASMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PSEUDOMONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PSOAS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RENAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RICKETTSIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SALMONELLOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SALPINGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SCROTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SIALOADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN CANDIDA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STOMA SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUBDIAPHRAGMATIC ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUPERINFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TORULOPSIS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TRACHEITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS GASTROINTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TUBO-OVARIAN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VAGINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VARICELLA ZOSTER PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VIRAL PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VULVAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VULVAL CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL MYCOTIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC LEAK</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLON INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COMPLICATIONS OF TRANSPLANTED KIDNEY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL DISORDER POSTOPERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STOMA COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL ANASTOMOSIS COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MENISCUS INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NERVE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX TRAUMATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROCEDURAL INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROCEDURAL NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PUBIS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SCAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SPLENIC RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STOMA SITE INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUTURE RELATED COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TRANSFUSION REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TRAUMATIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UTERINE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WOUND COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WOUND DECOMPOSITION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WOUND DEHISCENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WOUND SECRETION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BACTERIAL TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CSF CULTURE POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CULTURE URINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OXYGEN SATURATION DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROTEIN TOTAL ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>CACHEXIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOPROTEINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VITAMIN B12 DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FIBROMYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FISTULA DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FRACTURE NONUNION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LUPUS-LIKE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MOBILITY DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OSTEOPOROTIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PATHOLOGICAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POLYARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POLYCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SERONEGATIVE ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TENOSYNOVITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACROCHORDON</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA GASTRIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA OF COLON</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ADENOID CYSTIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANOGENITAL WARTS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER STAGE I, WITHOUT CANCER IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BREAST CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CARCINOID TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CARCINOID TUMOUR OF THE APPENDIX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CARCINOID TUMOUR OF THE GASTROINTESTINAL TRACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLANGIOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLON CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLON CANCER STAGE I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLORECTAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FOLLICLE CENTRE LYMPHOMA, FOLLICULAR GRADE I, II, III STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GALLBLADDER ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GALLBLADDER CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HODGKIN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTRADUCTAL PAPILLOMA OF BREAST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTRAOCULAR MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INVASIVE DUCTAL BREAST CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LIPOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MENINGIOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>METASTASES TO BONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>METASTASES TO PERITONEUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>METASTATIC LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MYCOSIS FUNGOIDES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PARATHYROID TUMOUR BENIGN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SEMINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINE ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINE CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF THE CERVIX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF THE VULVA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>T-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TESTIS CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VULVAL CANCER STAGE 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ARACHNOIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ATAXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CEREBRAL ARTERY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CEREBRAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CEREBROSPINAL FLUID LEAKAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEMYELINATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EXTRAPYRAMIDAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERCOSTAL NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL VENOUS SINUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEUROLOGICAL DECOMPENSATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OPTIC NEURITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RUPTURED CEREBRAL ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TRIGEMINAL NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UNRESPONSIVE TO STIMULI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UPPER MOTOR NEURONE LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABORTION SPONTANEOUS COMPLETE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COMPLICATION OF DELIVERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DELAYED DELIVERY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ECTOPIC PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FOETAL DEATH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYDROPS FOETALIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PRE-ECLAMPSIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PREMATURE RUPTURE OF MEMBRANES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROLONGED PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RUPTURED ECTOPIC PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STILLBIRTH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AFFECTIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRUG DEPENDENCE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EATING DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OBSESSIVE-COMPULSIVE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ACUTE PRERENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHRONIC KIDNEY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GLOMERULONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEPHROTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE UROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PELVI-URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STRESS URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TUBULOINTERSTITIAL NEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>URETERIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>URGE INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BARTHOLIN'S CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BREAST DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BREAST HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CERVICAL DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CERVIX DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CERVIX INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL THICKENING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENDOMETRIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FEMALE GENITAL TRACT FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GENITAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFERTILITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OEDEMA GENITAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST RUPTURED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PELVIC ADHESIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PELVIC FLUID COLLECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERINEAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERINEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROSTATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROSTATOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VAGINAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VAGINAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VARICOCELE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BRONCHOLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NASAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NASAL POLYPS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM DEVIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NASAL TURBINATE ABNORMALITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PULMONARY SARCOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BLISTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CUTANEOUS LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DERMATITIS PSORIASIFORM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DERMATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ERYTHEMA MULTIFORME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ERYTHEMA NODOSUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GUTTATE PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HENOCH-SCHONLEIN PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HIDRADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERTRIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PAIN OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PUSTULAR PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PYODERMA GANGRENOSUM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RASH FOLLICULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABORTION INDUCED</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLOSTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRUG DETOXIFICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYSTERECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL ANASTOMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>AORTIC DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>AORTIC THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BEHCET'S SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PELVIC VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERIPHERAL EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POLYARTERITIS NODOSA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SHOCK HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="958" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERGAMMAGLOBULINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MACROCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SPLENIC VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>HEREDITARY FRUCTOSE INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERTROPHIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOACUSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>AUTOIMMUNE THYROIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BASEDOW'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERPARATHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLEPHARITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHALAZION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EPISCLERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EYE INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IRIDOCYCLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IRITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PUNCTATE KERATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SCLERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VISUAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ADHESIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL TENDERNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL FISSURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANORECTAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANORECTAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANORECTAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANORECTAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>APHTHOUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHAPPED LIPS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHEILITIS GRANULOMATOSA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COELIAC DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CROHN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DENTAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DUODENAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTEROCOLONIC FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTEROCUTANEOUS FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FAECAL INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FISTULA OF SMALL INTESTINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FREQUENT BOWEL MOVEMENTS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL MOTILITY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GINGIVAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GLOSSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERNIAL EVENTRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ILEAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>JEJUNAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LIP SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOCALISED INTRAABDOMINAL FLUID COLLECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MUCOUS STOOLS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OBSTRUCTION GASTRIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ODYNOPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL FOOD IMPACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORAL LICHEN PLANUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORAL MUCOSAL ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PALATAL DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA ORAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERIANAL ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PROCTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL TENESMUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TONGUE DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TOOTH LOSS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRUG EFFECT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRUG INEFFECTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FEELING ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FEELING COLD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GRANULOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INJECTION SITE IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INJECTION SITE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INJECTION SITE RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INJECTION SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INJECTION SITE WARMTH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOCALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PARADOXICAL DRUG REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PUNCTURE SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>XEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS SCLEROSING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLESTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FATTY LIVER ALCOHOLIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GALLBLADDER DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATIC CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATIC FIBROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATIC STEATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATOCELLULAR INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEPATOSPLENOMEGALY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SERUM SICKNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANGULAR CHEILITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BARTHOLIN'S ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BARTHOLINITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BODY TINEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BORRELIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CAMPYLOBACTER GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CAMPYLOBACTER INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CANDIDA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHLAMYDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHRONIC HEPATITIS C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHRONIC SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CRYPTOCOCCOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CRYPTOSPORIDIOSIS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DERMO-HYPODERMITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ECZEMA INFECTED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTEROBIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EPSTEIN-BARR VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EYE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EYE INFECTION STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FUNGAL SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NOROVIRUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GENITAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GENITAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GENITAL INFECTION FUNGAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GINGIVAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GYNAECOLOGICAL CHLAMYDIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERPES OPHTHALMIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERPES VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HIV INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INCISION SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFECTIOUS MONONUCLEOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INFUSION SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LATENT TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MASTITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MASTOIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MOLLUSCUM CONTAGIOSUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MYCOBACTERIUM MARINUM INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NAIL CANDIDA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NASAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ONYCHOMYCOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OPHTHALMIC HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORAL FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ORAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OVERGROWTH BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PAPILLOMA VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PAROTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PELVIC INFLAMMATORY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERIODONTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONIA KLEBSIELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PSEUDOMONAS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PURULENT DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RASH PUSTULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RECTAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SALPINGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SIALOADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN CANDIDA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STOMA SITE ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STOMA SITE CANDIDA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUPERINFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TINEA PEDIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TRICHOPHYTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UREAPLASMA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION ENTEROCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UTERINE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VAGINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VAGINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VARICELLA ZOSTER VIRUS INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL MYCOTIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENT AT HOME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHEST INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FOREIGN BODY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STOMA SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WOUND SECRETION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ALPHA 1 FOETOPROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BLOOD CHOLESTEROL INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BLOOD IRON DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BLOOD TRIGLYCERIDES INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CRYSTAL URINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DOUBLE STRANDED DNA ANTIBODY POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GIARDIA TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HUMAN PAPILLOMA VIRUS TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MYCOBACTERIUM TUBERCULOSIS COMPLEX TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELLS URINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SERUM FERRITIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STOOL TRYPSIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TUBERCULIN TEST POSITIVE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VITAMIN B12 DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HAEMOCHROMATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LATENT AUTOIMMUNE DIABETES IN ADULTS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POLYDIPSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VITAMIN B12 DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VITAMIN D DEFICIENCY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANKYLOSING SPONDYLITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FIBROMYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FISTULA DISCHARGE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GOUTY ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LUPUS-LIKE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OSTEITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS OF JAW</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OSTEOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>POLYARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SJOGREN'S SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SPINAL DEFORMITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SPONDYLOARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TEMPOROMANDIBULAR JOINT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TENDON DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TENOSYNOVITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ANOGENITAL WARTS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BOWEN'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CARCINOMA IN SITU OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHOLESTEATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COLON ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MELANOCYTIC NAEVUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PENILE WART</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN INTRACRANIAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BURNING SENSATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CLUSTER HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEMYELINATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MIGRAINE WITH AURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SPEECH DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TEMPORAL LOBE EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>TRIGEMINAL NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VIITH NERVE PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>UTERINE CONTRACTIONS DURING PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANTICIPATORY ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MENTAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PANIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SLEEP DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>STRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER SPASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHRONIC KIDNEY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>IGA NEPHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>URETHRAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BALANOPOSTHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CERVICAL DYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ERECTILE DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>FEMALE GENITAL TRACT FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>MENOPAUSAL SYMPTOMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>UTERINE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VULVAL ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VULVAR EROSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>BRONCHITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DYSPNOEA PAROXYSMAL NOCTURNAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EMPHYSEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPOVENTILATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NASAL DRYNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NASAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NASAL SEPTUM DEVIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NASAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SPUTUM DISCOLOURED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>THROAT TIGHTNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VOCAL CORD DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ACTINIC KERATOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ALOPECIA AREATA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CHRONIC PIGMENTED PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>CUTANEOUS LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DERMAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DERMATITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DERMATITIS ATOPIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DERMATITIS BULLOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DERMATITIS PSORIASIFORM</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ERYTHEMA MULTIFORME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ERYTHEMA NODOSUM</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GRANULOMA SKIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>GUTTATE PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HENOCH-SCHONLEIN PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HIDRADENITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>INTERTRIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LICHEN PLANUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>LICHEN SCLEROSUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PALMOPLANTAR KERATODERMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PRURIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PRURITUS GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>PYODERMA GANGRENOSUM</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RASH GENERALISED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RASH MACULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RASH PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RASH PRURITIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>RASH VESICULAR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>ROSACEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN EXFOLIATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN FISSURES</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN PLAQUE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN REACTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>TONSILLECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="5025"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5025"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Information</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

